Procter & Gamble Health Limited (PGHL.BO)
INR 5064.8
(-0.15%)
INR 5064.8
(-0.15%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 11.51 Billion INR | -6.37% |
| 2022 | 12.29 Billion INR | 10.34% |
| 2021 | 11.14 Billion INR | 12.48% |
| 2020 | 9.9 Billion INR | 9.68% |
| 2019 | 9.03 Billion INR | 10.41% |
| 2018 | 8.18 Billion INR | 17.2% |
| 2017 | 6.98 Billion INR | -29.66% |
| 2016 | 9.92 Billion INR | 5.87% |
| 2015 | 9.37 Billion INR | 8.65% |
| 2014 | 8.62 Billion INR | 8.68% |
| 2013 | 7.93 Billion INR | 15.8% |
| 2012 | 6.85 Billion INR | 23.84% |
| 2011 | 5.53 Billion INR | 8.75% |
| 2010 | 5.09 Billion INR | 7.6% |
| 2009 | 4.73 Billion INR | 21.48% |
| 2008 | 3.89 Billion INR | 23.7% |
| 2007 | 3.14 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.13 Billion INR | 10.4% |
| 2023 FY | 11.51 Billion INR | -6.37% |
| 2023 Q4 | 2.83 Billion INR | 12.44% |
| 2023 Q3 | 2.52 Billion INR | -18.55% |
| 2023 Q2 | 3.09 Billion INR | 1.65% |
| 2023 Q1 | 3.04 Billion INR | 1.25% |
| 2022 Q4 | 3.01 Billion INR | -6.15% |
| 2022 FY | 12.29 Billion INR | 10.34% |
| 2022 Q3 | 3.2 Billion INR | 3.53% |
| 2022 Q2 | 3.09 Billion INR | 4.17% |
| 2022 Q1 | 2.97 Billion INR | 8.79% |
| 2021 Q1 | 2.72 Billion INR | 2.0% |
| 2021 Q3 | 2.67 Billion INR | -3.63% |
| 2021 Q4 | 2.73 Billion INR | 2.13% |
| 2021 Q2 | 2.77 Billion INR | 1.87% |
| 2021 FY | 11.14 Billion INR | 12.48% |
| 2020 Q3 | 2.19 Billion INR | -8.77% |
| 2020 Q2 | 2.4 Billion INR | -9.0% |
| 2020 FY | 9.9 Billion INR | 9.68% |
| 2020 Q1 | 2.63 Billion INR | 31.23% |
| 2020 Q4 | 2.67 Billion INR | 22.04% |
| 2019 FY | 9.03 Billion INR | 10.41% |
| 2019 Q3 | 2.28 Billion INR | 0.0% |
| 2019 Q1 | 2.25 Billion INR | -3.62% |
| 2019 Q4 | 2.01 Billion INR | -11.81% |
| 2018 Q2 | 2.04 Billion INR | -9.62% |
| 2018 FY | 8.18 Billion INR | 17.2% |
| 2018 Q4 | 2.33 Billion INR | 1.13% |
| 2018 Q3 | 2.31 Billion INR | 13.03% |
| 2018 Q1 | 2.26 Billion INR | 2.66% |
| 2017 FY | 6.98 Billion INR | -29.66% |
| 2017 Q4 | 2.2 Billion INR | 11.16% |
| 2017 Q3 | 1.98 Billion INR | 10.98% |
| 2017 Q2 | 1.78 Billion INR | -13.26% |
| 2017 Q1 | 2.05 Billion INR | 24.54% |
| 2016 Q1 | 2.69 Billion INR | 1.05% |
| 2016 FY | 9.92 Billion INR | 5.87% |
| 2016 Q4 | 1.65 Billion INR | -27.81% |
| 2016 Q3 | 2.28 Billion INR | -8.36% |
| 2016 Q2 | 2.49 Billion INR | -7.19% |
| 2015 Q4 | 2.66 Billion INR | 26.69% |
| 2015 Q1 | 2.45 Billion INR | 2.12% |
| 2015 Q2 | 2.31 Billion INR | -5.65% |
| 2015 Q3 | 2.1 Billion INR | -9.35% |
| 2015 FY | 9.37 Billion INR | 8.65% |
| 2014 Q1 | 2.14 Billion INR | -7.89% |
| 2014 Q4 | 2.4 Billion INR | 26.91% |
| 2014 Q3 | 1.89 Billion INR | -17.09% |
| 2014 FY | 8.62 Billion INR | 8.68% |
| 2014 Q2 | 2.28 Billion INR | 6.77% |
| 2013 Q2 | 2.15 Billion INR | 6.63% |
| 2013 Q3 | 1.87 Billion INR | -13.03% |
| 2013 Q4 | 2.32 Billion INR | 24.31% |
| 2013 FY | 7.93 Billion INR | 15.8% |
| 2013 Q1 | 2.01 Billion INR | 0.76% |
| 2012 Q1 | 1.81 Billion INR | 1.26% |
| 2012 Q4 | 2 Billion INR | 13.39% |
| 2012 Q3 | 1.76 Billion INR | 10.73% |
| 2012 FY | 6.85 Billion INR | 23.84% |
| 2012 Q2 | 1.59 Billion INR | -11.96% |
| 2011 Q3 | 1.36 Billion INR | 8.03% |
| 2011 Q1 | 1.63 Billion INR | 0.0% |
| 2011 FY | 5.53 Billion INR | 8.75% |
| 2011 Q4 | 1.78 Billion INR | 30.87% |
| 2011 Q2 | 1.26 Billion INR | -22.55% |
| 2010 FY | 5.09 Billion INR | 7.6% |
| 2009 FY | 4.73 Billion INR | 21.48% |
| 2008 FY | 3.89 Billion INR | 23.7% |
| 2007 FY | 3.14 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alkem Laboratories Limited | 126.67 Billion INR | 90.912% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -173.309% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 81.164% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 11.136% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 95.989% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -2775.612% |
| Eris Lifesciences Limited | 20.09 Billion INR | 42.699% |
| FDC Limited | 19.42 Billion INR | 40.747% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 49.577% |
| Ipca Laboratories Limited | 76.22 Billion INR | 84.896% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -451.629% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -2183.272% |
| Laurus Labs Limited | 50.01 Billion INR | 76.983% |
| Lupin Limited | 200.1 Billion INR | 94.247% |
| Medicamen Biotech Limited | 1.79 Billion INR | -542.064% |
| Medico Remedies Limited | 1.44 Billion INR | -694.407% |
| Megasoft Limited | 373.95 Million INR | -2978.622% |
| NATCO Pharma Limited | 40.02 Billion INR | 71.233% |
| Piramal Pharma Limited | 81.71 Billion INR | 85.911% |
| Sigachi Industries Limited | 3.98 Billion INR | -188.568% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 7.036% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 97.626% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -9.503% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -344.084% |
| Themis Medicare Limited | 3.81 Billion INR | -201.566% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 89.145% |
| Valiant Laboratories Limited | 1.82 Billion INR | -532.362% |
| Wanbury Limited | 5.75 Billion INR | -99.993% |
| Windlas Biotech Limited | 6.3 Billion INR | -82.463% |
| ZIM Laboratories Limited | 3.67 Billion INR | -213.332% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 93.948% |
| Ajanta Pharma Limited | 42.08 Billion INR | 72.646% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 10.121% |
| Achyut Healthcare Limited | 61.36 Million INR | -18659.634% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1003.426% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -1423.933% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 36.587% |
| Alpa Laboratories Limited | 1.08 Billion INR | -958.737% |
| Gufic Biosciences Limited | 8.06 Billion INR | -42.718% |
| Ind-Swift Limited | 5.02 Billion INR | -129.121% |
| Indoco Remedies Limited | 17.89 Billion INR | 35.664% |
| Hester Biosciences Limited | 3.04 Billion INR | -278.025% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -49.467% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -143.18% |
| RPG Life Sciences Limited | 5.82 Billion INR | -97.794% |
| Mankind Pharma Limited | 103.34 Billion INR | 88.86% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 90.254% |
| Unichem Laboratories Limited | 16.57 Billion INR | 30.539% |
| Bal Pharma Limited | 3.39 Billion INR | -239.385% |
| Strides Pharma Science Limited | 40.51 Billion INR | 71.582% |
| Venus Remedies Limited | 5.91 Billion INR | -94.651% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 82.824% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 95.876% |
| Divi's Laboratories Limited | 78.45 Billion INR | 85.325% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 31.639% |
| Shilpa Medicare Limited | 11.51 Billion INR | 0.03% |
| Aarti Drugs Limited | 25.28 Billion INR | 54.47% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 45.669% |
| Suven Life Sciences Limited | 116.92 Million INR | -9745.804% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 66.958% |
| Hikal Limited | 17.84 Billion INR | 35.489% |
| Sequent Scientific Limited | 13.69 Billion INR | 15.95% |
| Novartis India Limited | 3.35 Billion INR | -243.588% |
| Granules India Limited | 45.06 Billion INR | 74.453% |
| Wockhardt Limited | 27.89 Billion INR | 58.721% |
| Brooks Laboratories Limited | 794.86 Million INR | -1348.379% |
| Neuland Laboratories Limited | 15.58 Billion INR | 26.134% |
| Morepen Laboratories Limited | 17.01 Billion INR | 32.354% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -645.768% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -212.338% |